UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
April 16, 2018
________________
NOVO NORDISK A/S
(Exact name of Registrant as specified in its charter)
Novo Allé
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F
| Form 20-F [X] | Form 40-F [ ] |
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
| Yes [ ] | No [X] |
If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g-32(b):82-________
Novo Nordisk A/S – Share repurchase programme
Bagsværd, Denmark, 16 April 2018 – On 5 February 2018, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR), also referred to as the Safe Harbour rules. This programme is part of the overall share repurchase programme of up to DKK 14 billion to be executed during a 12-month period beginning 1 February 2018.
Under the programme initiated 5 February 2018, Novo Nordisk will repurchase B shares for an amount up to DKK 2.5 billion in the period from 6 February 2018 to 30 April 2018.
Since the announcement as of 9 April 2018, the following transactions have been made under the programme:
| Number of B shares |
Average purchase price |
Transaction value, DKK | |
| Accumulated, last announcement | 6,133,617 | 1,873,335,009 | |
| 9 April 2018 | 150,000 | 300.02 | 45,002,945 |
| 10 April 2018 | 124,420 | 303.54 | 37,765,856 |
| 11 April 2018 | 151,900 | 302.42 | 45,938,021 |
| 12 April 2018 | 140,000 | 300.22 | 42,030,383 |
| 13 April 2018 | 145,000 | 298.97 | 43,350,022 |
| Accumulated under the programme | 6,844,937 | 2,087,422,236 |
The details for each transaction made under the share repurchase programme are published on novonordisk.com.
With the transactions stated above, Novo Nordisk owns a total of 69,907,173 B shares of DKK 0.20, corresponding to 2.8% of the share capital, as treasury shares. The total amount of A and B shares in the company is 2,500,000,000 including treasury shares.
Page 2 of 2
Novo Nordisk expects to repurchase B shares for an amount up to DKK 14 billion during a 12-month period beginning 1 February 2018. As of 13 April 2018, Novo Nordisk has repurchased a total of 9,932,347 B shares at an average share price of DKK 306.18 per B share equal to a transaction value of DKK 3,041,123,185.
Novo Nordisk is a global healthcare company with more than 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat obesity, haemophilia, growth disorders and other serious chronic diseases. Headquartered in Denmark, Novo Nordisk employs approximately 42,100 people in 79 countries and markets its products in more than 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube
Further information
| Media: | ||
| Anne Margrethe Hauge | +45 4442 3450 | amhg@novonordisk.com |
| Ken Inchausti (US) | +1 609 786 8316 | kiau@novonordisk.com |
| Investors: | ||
| Peter Hugreffe Ankersen | +45 3075 9085 | phak@novonordisk.com |
| Anders Mikkelsen | +45 3079 4461 | armk@novonordisk.com |
| Christina Kjær | +45 3079 3009 | cnje@novonordisk.com |
Novo Nordisk A/S Investor Relations |
Novo Allé 2880 Bagsværd Denmark |
Telephone: +45 4444 8888 |
Internet: 24 25 67 90 |
| Company announcement No 32 / 2018 | |||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
| Date: April 16, 2018 |
NOVO NORDISK A/S
Lars Fruergaard Jørgensen Chief Executive Officer |